Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Claims of any pending patent application would need to be drafted to distinguish from the related art that follows the blog article cited by DMC8. The blogger himself suggested Vascepa as a suitable med to use for migraines. What have Amarin researchers done with use of Vascepa in the art of treating migraines is my question….anything prior to the publication of the blog? Could Amarin as assignee use the blogger alone as the inventor? That might cost Amarin some $$$$.
Most, if not all, companies have insurance that covers catastrophic damages to company assets. Fires, floods, equipment failures or earthquakes, such as those that have occurred lately in areas of California where CDMO’s plants are located, are examples of such insurance. Even insurance that would cover damages resulting from an airplane crashing into a company’s plant or office facilities might be possible with appropriate insurance premium. I admit I have not checked, but does CDMO have an insurance policy that covers management negligence in performance of its corporate duties?
Do not forget: New patents in suit(s) in Delaware (and New Jersey ?) that are presumed valid. Present CAFC appeal by Amarin only involves infringement issue now; the CAFC decision/opinion will be important to Sarissa/Denner/Holt.
Per CNBC-TV interview of a member of Congress, legislation authorizing at least medical uses of marijuana will be introduced next week.
SBUX trading down at ~ $75/share on drop in sales, earnings in U.S., China and Middle East. Spirited debate on remedies (among Faber, Cramer and SBUX CEO on CNBC-TV) to improve SBUX waiting time for service has concluded for now.
That sale by CEO is just enough to pay taxes due on vested RSUs or options, per purpose or reason for sale.
Re “PFE non GLP-1, not named”: Per CNBC-TV this morning, PFE is establishing an online platform from which it intends to sell unidentified medicines directly to public. I have lost 25-30 lbs since I was first prescribed Amarin’s FDA-approved Vascepa in April 2013, off-label, in connection with my Type-1 diabetes. Vascepa is not a GLP-1, and PFE is selling Vascepa to doctors in all provinces of Canada to help patients reduce risk from CVD events. PFE has ample money to pay for media TV ads, much like BMY is now doing for some of its meds: “Check with your doctor to see if XXX is right for you.”
Is PFE’s plan to establish a new platform to sell medicines directly to public in U.S. part of your projected rally? PFE could pay for ads to check with your doctor to see if Vascepa is right for you, the patient, much like BMY is doing for its Opdivo and Yervoy combo.
Kiwi, have you had your blood serum level of Lp(a) tested or analyzed yet? Ask Drs. Bhatt and Mason if you should, and see the April 6 Amarin PRs for reasons why you should.
I wonder whether Vascepa will be protected from attempted imitation under the “No Fakes Act” to be introduced in Congress this coming week.
Thanks for the link to the New Yorker article, djohn. I have 2 reasons for reading it and finding it significant:
1) Cohen’s family fund has made a large investment in CDMO, currently one of our largest investments in both capital that we have invested and today’s market value. Our ~ 55k shares have returned to a diminished LTCG state at $7.63, but nowhere near where we were a year ago at a CDMO share price of ~ $18.60.
2) One of the SDNY prosecutors mentioned in the article is Richard Zabel. He is the son of Bill Zabel, one of my high school friends who entered Princeton University in 1954 and accounts for my interest in Princeton. At his urging, I applied to Princeton in 1955, received a scholarship, but got a better scholarship from Northwestern where I graduated in 1959. I accepted the TRI fellowship I received from Princeton for graduate school, and my degree there followed in 1962.
Last I heard/read about Bill, he was a named partner in that powerhouse NYC law firm where he specialized in trusts and estates, and wealth management. He was one of the attorneys representing the wife of Jack Welch, former GE CEO, in her battle for fair estate value in that highly public divorce matter following Jack’s “escapades,” different perhaps from the “less public escapade” we find CDMO has caused us to be in today.
Wouldn’t the 227 patients Greek trial suffice? See CaptBeer’s post this evening. Does Greek population differ from populations of France or Germany significantly?
See 60 minutes tonight, CBS-TV at 7:00 pm. Reports veteran-acquired PTSD can be “contagious” in the sense that veteran brings back and repeatedly tells wife and child horrific stories of explosions wiping out comrades in same location near him. The wife becomes despondent herself in constant caring of a now suicidal husband. Much caring of both is now in the hands of older child…and the story continues with child also becoming depressed. This husband eventually recovers, finds a job, and is able to support the family. The wife and child are interviewed, and relate the above story.
I wonder whether investigators in the BRAVE trial are seeing signs of the above developments in the veteran population studied and interviewed. Are family members also interviewed?
You are correct, and kiwi continues to be out to lunch in failing to acknowledge a line in one of DMC8’s links today that the Vascepa market is being retained because freedom from pancreatitis has not been shown by a generic clinical trial. The generics have the burden of proof.
Why don’t you transfer those shares from your IRA to your taxable account(s) if you need ST or LT capital losses to offset ST or LT capital gains?
CaptB: Do you really intend/mean to imply that anyone who happens to read your message on the X/twitter site is “stupid” or ignorant? How does “EPA” correlate with the 18 page Citizen’s Petition you link/quote? Am I wrong that EPA is contained in drug supplements and other formulations in various quantities that also don’t reduce risk from CVDs? Your message doesn’t compare well to Amarin’s response to the petition that the FDA Commissioner and/or his enforcement staff will read, IMO.
Reading its earnings reports, it’s apparent that BMY is experiencing the same problems that AMRN faced years ago. Sales of key drugs have fallen, notwithstanding multiple and extensive TV ads directed to patients and doctors. A few of those drugs will have generic competition on patent expiration in addition to negotiated price reduction in light of recent Congressional legislation. 2500 person layoffs are in the future for BMY. Debt accrued for a pair of acquisitions this year also is a problem in light of much higher interest rates in 2024, in contrast to AMRN that has no debt.
BTW, we deliberately purchased those 100 AMRN shares at $0.9638/share AH last evening. I had intended to purchase up to 900 more but a retirement party we attended lasted beyond last trade at 8 pm.
Some sad history: New Jersey Rep. Donald Payne Jr. dies from a cardiac episode related to complications from diabetes at age 65. He had been hospitalized, unconscious, since early April, per reports in N.J. newspapers.
How does fat help? Does the source of fat (e.g., nuts) make a difference?
Have you picked a date for contest 20 to start?
The total triglyceride-lowering market is ~7% of the total market that Amarin is aiming at. The remaining 93% is the CVD market for which no generic has an FDA-approved ANDA or sANDA.
Let’s continue this debate tomorrow. We don’t seem to have helped Amarin share price today. I just received a news alert about an explosion at an Iran oil refinery. That news may have a further negative effect on all sectors of the market tomorrow but for the defense industry sector.
Ask sleven or CaptBeer to find the original Complaint that Amarin filed in the Nevada court. The 6 patents will be cited there that H and DRL were accused of infringing. It’s past dinner time for me.
Question to both Stockboy and BbI: Were all claims of Amarin’s 6 patents involved in the Nevada suit limited to IPE, icosapent ethyl, as opposed to defined amounts of highly pure EPA? Thanks to both of you for your analysis. Restoration of some claims of those patents, particularly the dependent claim you focus on, could still be waved in front of H’s face to force a possible settlement. The Supreme Court’s opinion in Hazel-Atlas remains in play, IMO. DRL and TEVA should also be concerned.
So far C has been right on his calls re AAPL and NVDA: Buy at a lower price(whatever that price is), hold and do not sell(unless you bought at the all time high and need a tax loss). I will abide by that recommendation.
He stuck a Pitchfork in AMRN last year: “Too speculative, stay away, do not buy.” He may now be missing a recovery with Amarin’s Vascepa now approved and reimbursed in all Canadian provinces; approved in China, Australia and New Zealand; approved by EU(EMEA) with reimbursement in UK, SPAIN, and being negotiated in remaining countries of EU; FDA approved in U.S., with patient’s insurance permitting Amarin to maintain a 57% market share against 5-6 generics who have no sANDA approved by FDA for Vascepa treatment of the much broader CVD indication. Take a look at the posters/abstracts featuring Vascepa that were presented at ACC earlier this month.
Typo: “cerebral” should read “cerebrospinal(CBS)”.
Do the patient’s cerebral blood flow biomarkers being investigated in BRAVE also include Lp(a)?
Does anyone remember whether BRAVE clinical trial includes the observation/measurement of patient’s Lp(a) levels in the respective Vascepa treatment and placebo arms?
CaptBeer, the graph in your post is the most complete summary of Reduce-It trial results that I have seen. The authors of the large U.Cal.Irvine Lp(a) study(lead investigator Wong et al), posted by DMC8, were obviously unaware of the data presented by Bhatt et al at ACC (that was the subject of several abstracts/posters also published in JACC) when they said there is “no treatment available yet.” My wife and I are signing up for a Lp(a) test.
Shares of Amarin are currently trading at an unjustified low value. Has there been a leak of results of proxy votes submitted on April 12 due date?
I agree—icosapent ethyl is not found in fish, but was manufactured/synthesized in a laboratory by its inventors.
I have a chart showing the content of omega-3 in various fish. Chewing on salmon, smoked salmon, smoked brook trout seems to increase the benefit of Vascepa for me while tilapia flunks.
Another ambiguity: In our TD Ameritrade account remaining, the Latest Earnings Announcement is set for today, 4/15/2024, but it sets the Upcoming Earnings Announcement as 4/18/2024. I gather 4/18 is correct.
Iran’s drone attack against Israel has begun, per news alert just received.
Beamr(BMR) is one of the early partners of NVDA mentioned in your post. NVDA shareholders should investigate BMR’ s website and PRs to see the image reduction technology that BMR brings to the table to enhance the share value of NVDA. We hold 600 shares of BMR, currently quoted at $6.20/share. We also hold 755 shares of NVDA at a split-adjusted cost or basis of $4.3115/share, purchased over a decade ago. Ready for another NVDA stock split.
Looked at ALPN very early this morning but, before I was able to accumulate funds in IRA to buy, it had already advanced in share price to near acquisition value. Gave up on what looked like a good play—will look at the other one over the weekend.
Some of us will remember the essentially “free advertising” Amarin obtained when the top-line and final data results from Reduce-It clinical trial were released in 2019-2020. Long stories with video interviews of Amarin’s CEO, Dr. Bhatt and various other knowledgeable cardiologists and endocrinologists were featured in the Washington Post, New York Times, Wall Street Journal and Bloomberg(Vascepa “works”, said JT), among many others. Prospective patients and prescribing doctors read those stories.
I am confident that Amarin management and BOD, and Sarissa/Dr. Denner will find a timely way to make those publications aware of Vascepa’s new CVD risk reduction and other disease treatment data that Amarin has accumulated since, particularly the data released this past week at the ACC scientific session—why and how Vascepa “works.”
Not only “what they are generic for”, but “what they are not shown with evidence to be generic for” would be better, IMO, in light of the facts of this case. The fact that FDA has approved the generic for one indication but has not approved the generic for another, second indication should be part of permissible conduct to escape infringement.
New York Times reports a FAA whistleblower investigation re design flaws in Boeing Dreamliner.
Thanks for the link and “dialog” between you and jfmcrr. My PCP, a former NIH research physician, prescribed tadalafil for me a few years ago. Both my retina specialist and ophthalmologist were happy to see it on my med list also after my cataract removal. I have no cardiologist that I regularly see.
I’ve read a report that the plane involved was manufactured by BA in 2015, in service for 9 years. This shifts the Denver incident to LUV(Southwest) maintenance.